MedTrace Logo

A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older

NCT02133456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166240

Last updated 2014-05-08

No results posted yet for this study

Summary

To monitor the safety of Shanghai Institute of Biological Products Company's influenza vaccine in subjects aged 3 years and older through Adverse Events Following Immunization Surveillance System of China.

The hypothesis is that there is no significant difference in the occurrence of adverse events among influenza vaccines manufactured by SIBP and other companies.

Conditions

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    collaborator INDUSTRY

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Jiang Wu, Master · Beijing Centers for Disease Prevention and Control, China

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-03-31
Completion
2014-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133456 on ClinicalTrials.gov